VG Life Sciences control over 40 U.S. and foreign patents and/or pending patent applications through licensing agreements with universities, as well as Scott & White Healthcare.
The licensing rights significant to VGLS’ core business are covered by three exclusive agreements. VGLS’ primary asset is its intellectual property, which is maintained and safeguarded by Wolf, Greenfield & Sacks, P.C. in Boston, one of the world’s premier intellectual property firms.
Aug. 25, 2009: Secured worldwide exclusive license agreement with the University of Colorado for the rights to patents, patent applications, and technologies pertaining to Targeted Peptide Technology developed by Dr. Newell-Rogers at the University. License encompasses 13 pending U.S. and foreign patent applications and one issued U.S. patent.
METABOLIC DISTRIBUTION LICENSE
Nov. 22, 2009: Obtained worldwide exclusive license from the University of Colorado for the rights to patents, patent applications, and technologies developed by Dr. Newell-Rogers while working at the University of Colorado and the University of Vermont. License encompasses 14 pending U.S. and foreign patent applications and 13 issued U.S. and foreign patents.
SCOTT & WHITE HEALTHCARE LICENSE
July 18, 2013: Granted worldwide exclusive license from Scott & White Healthcare for the rights to patents, patent applications, and technologies developed by Dr. Newell-Rogers and owned by Texas A&M University and Scott & White Healthcare. License encompasses eight pending U.S. and foreign patent applications and one issued patent.